Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
Richard Ang, Svetlana Mastitskaya, Patrick S. Hosford, et al.
Circulation Arrhythmia and Electrophysiology (2018) Vol. 11, Iss. 10
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma, Zhenghong Liu, Iqra Ilyas, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 8, pp. 2050-2068
Open Access | Times Cited: 154
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 132
Cardiac Vagus and Exercise
Alexander V. Gourine, Gareth L. Ackland
Physiology (2018) Vol. 34, Iss. 1, pp. 71-80
Open Access | Times Cited: 92
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
Johanna Helmstädter, Karin Keppeler, Leonie Küster, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 659-676
Open Access | Times Cited: 57
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 836-836
Open Access | Times Cited: 26
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Anniek F. Lubberding, Simon Veedfald, Jonathan Samuel Achter, et al.
Cardiovascular Research (2024)
Open Access | Times Cited: 8
Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke
Shereen Nizari, Marina Basalay, Philippa Chapman, et al.
Basic Research in Cardiology (2021) Vol. 116, Iss. 1
Open Access | Times Cited: 52
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Mario Schubert, Sinah Hansen, Julian Leefmann, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 42
Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets
Wanlin Ye, Kun Han, Maodi Xie, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 8, pp. 936-948
Open Access | Times Cited: 4
Genetic Implications of Fatty Tissue for the Development of Ventricular Arrhythmias
Raluca Sirbu Prisecaru, Oana Purcar, Ioan Maniţiu
Cardiogenetics (2025) Vol. 15, Iss. 1, pp. 8-8
Open Access
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101405-101405
Closed Access | Times Cited: 16
PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
Marie K. Holt, Daniel R. Cook, Daniel I. Brierley, et al.
Molecular Metabolism (2020) Vol. 39, pp. 101024-101024
Open Access | Times Cited: 26
Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin
Refaat A. Eid, Mohammad Khalil, Mahmoud A. Alkhateeb, et al.
Cardiovascular Drugs and Therapy (2020) Vol. 35, Iss. 6, pp. 1095-1110
Closed Access | Times Cited: 26
Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts
Ayşegül Durak, Belma Turan
Journal of Physiology and Biochemistry (2022) Vol. 79, Iss. 2, pp. 297-311
Closed Access | Times Cited: 15
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
Sijin Wu, Wenzhao Lu, Zhongli Chen, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Double life: How GRK2 and β-arrestin signaling participate in diseases
Ruxu Zhai, Jonathan Snyder, Sarah Montgomery, et al.
Cellular Signalling (2022) Vol. 94, pp. 110333-110333
Open Access | Times Cited: 14
Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects
Anastasios Lymperopoulos, Jordana I. Borges, Renee A. Stoicovy
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 693-693
Open Access | Times Cited: 2
Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects
Renee A. Stoicovy, Natalie Cora, Arianna Perez, et al.
Inflammation Research (2024)
Closed Access | Times Cited: 2
Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics
Anthony J. Evans, Yu‐Long Li
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12464-12464
Open Access | Times Cited: 2
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Jean‐Philippe Krieger, Derek Daniels, Shin Lee, et al.
Comprehensive physiology (2024) Vol. 15, Iss. 1
Closed Access | Times Cited: 2
Glucagon‐like peptide‐1 receptor agonist treatment of high carbohydrate intake‐induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction
Ayşegül Durak, Erman Akkuş, Asena Gökçay Canpolat, et al.
Clinical and Experimental Pharmacology and Physiology (2021) Vol. 49, Iss. 1, pp. 46-59
Closed Access | Times Cited: 14
A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
Zhi‐Jie Liu, Ning Bian, Shaorong Wu, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Does Incretin Agonism Have Sustainable Efficacy?
Sok‐Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1842-1842
Open Access | Times Cited: 1
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Ayşegül Durak, Yusuf Olğar, et al.
Molecular and Cellular Biochemistry (2022) Vol. 477, Iss. 11, pp. 2609-2625
Closed Access | Times Cited: 5
Interplay Between Systemic Metabolic Cues and Autonomic Output: Connecting Cardiometabolic Function and Parasympathetic Circuits
Liliana Espinoza, Stephanie Fedorchak, Carie R. Boychuk
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top